University of California

Youhealth Biotech, Limited

Youhealth Oncotech, Limited

Other

Guangzhou Kangrui Biological Pharmaceutical Technology Co, Ltd.

Helio Health Inc.

Lantech, Inc.

Rui Hou

Kang Zhang

Lianghong Zheng

Gen Li

Xiaoping Chen

Yuwei Wang

Huimin Cai

Huifang Liang

Zhanguo Zhang

Zhimin Liu

Binhao Zhang

Bixiang Zhang

Guangxi Zang

Disclosed herein are methods and kits for identifying a subject as having liver cancer. Also provided herein are methods and kits for determining the prognosis of a subject having liver cancer and for determining the progression of liver cancer in a subject.

Liver cancer methylation markers and uses thereof

Disclosed herein are methods and kits for identifying a subject as having lung cancer. Also provided herein are methods and kits for determining the prognosis of a subject having lung cancer and for determining the progression of lung cancer in a subject.

Lung cancer methylation markers and uses thereof

Disclosed herein are methods and kits for identifying a subject as having colon cancer. Also provided herein are methods and kits for determining the prognosis of a subject having colon cancer and for determining the progression of colon cancer in a subject.

Colon cancer methylation markers and uses thereof

Disclosed herein are methods and compositions relating to synthesized nanopores. The synthesized nanopores can be used for detecting a target molecule (e.g. RNA, DNA, or peptide).

Methods and compositions for nanopore sequencing

Disclosed herein are methods and kits for identifying a subject as having breast cancer. Also provided herein are methods and kits for determining the prognosis of a subject having breast cancer and for determining the progression of breast cancer in a subject.

Breast and ovarian cancer methylation markers and uses thereof

Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).

Methods for evaluating, monitoring, and modulating aging process

Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Leukemia methylation markers and uses thereof

Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of ophthalmic diseases and conditions. Deep learning algorithms enable the automated analysis of ophthalmic images to generate predictions of comparable accuracy to clinical experts.

Deep learning-based diagnosis and referral of ophthalmic diseases and disorders

Disclosed herein are methods and kits for identifying a subject as having esophagus cancer, pancreatic cancer, or stomach cancer. Also provided herein are methods and kits for generating the methylation profile of a biomarker associated with esophagus cancer, pancreatic cancer, or stomach cancer.

Solid tumor methylation markers and uses thereof

Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.

Methylation markers for diagnosing hepatocellular carcinoma and lung cancer

The present invention provides sterols and uses thereof to treat vision disorders. In one embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat and/or prevent vision disorders in a subject. In another embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat cataract or blindness/impaired vision in a subject. In yet another embodiment, composition comprising lanosterol is used to dissolve amyloid-like fibrils of crystallin proteins.

Compositions and methods to treat vision disorders

[object Object]

Described herein are compounds that inhibit or prevent protein aggregation, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with protein aggregation.

Compounds for treating eye disorders or diseases

Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like. 

Growing community of inventors

Shenyang, China

Rui Hou